Work

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e17046

Authors: Mohammad O. Atiq, Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilusic, David James VanderWeele, Elias Bin Aris Chandran, Lisa M. Cordes, Helen Owens, Anna Couvillon, Amy Hankin, Monique Williams, William Douglas Figg, Peter L. Choyke, Liza Lindenberg, Esther Mena, William L. Dahut, James L. Gulley, Ravi Amrit Madan

Institutions: National Institutes of Health, National Cancer Institute, Northwestern University, Waikato District Health Board, Center for Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4281609281

Cites:

Cited by: 1

Related to: 10